315 related articles for article (PubMed ID: 30694219)
1. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.
Yamamoto TN; Lee PH; Vodnala SK; Gurusamy D; Kishton RJ; Yu Z; Eidizadeh A; Eil R; Fioravanti J; Gattinoni L; Kochenderfer JN; Fry TJ; Aksoy BA; Hammerbacher JE; Cruz AC; Siegel RM; Restifo NP; Klebanoff CA
J Clin Invest; 2019 Feb; 129(4):1551-1565. PubMed ID: 30694219
[TBL] [Abstract][Full Text] [Related]
2. Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy.
Anderson KG; Oda SK; Bates BM; Burnett MG; Rodgers Suarez M; Ruskin SL; Greenberg PD
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264436
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.
Weiss JM; Subleski JJ; Back T; Chen X; Watkins SK; Yagita H; Sayers TJ; Murphy WJ; Wiltrout RH
J Immunol; 2014 Jun; 192(12):5821-9. PubMed ID: 24808361
[TBL] [Abstract][Full Text] [Related]
4. Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy.
Wu B; Wu JM; Miagkov A; Adams RN; Levitsky HI; Drachman DB
J Immunol; 2001 Apr; 166(7):4773-9. PubMed ID: 11254740
[TBL] [Abstract][Full Text] [Related]
5. CART cells are prone to Fas- and DR5-mediated cell death.
Tschumi BO; Dumauthioz N; Marti B; Zhang L; Lanitis E; Irving M; Schneider P; Mach JP; Coukos G; Romero P; Donda A
J Immunother Cancer; 2018 Jul; 6(1):71. PubMed ID: 30005714
[TBL] [Abstract][Full Text] [Related]
6. CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30
Hong LK; Chen Y; Smith CC; Montgomery SA; Vincent BG; Dotti G; Savoldo B
Cancer Immunol Res; 2018 Oct; 6(10):1274-1287. PubMed ID: 30087115
[TBL] [Abstract][Full Text] [Related]
7. Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.
Zhu J; Powis de Tenbossche CG; Cané S; Colau D; van Baren N; Lurquin C; Schmitt-Verhulst AM; Liljeström P; Uyttenhove C; Van den Eynde BJ
Nat Commun; 2017 Nov; 8(1):1404. PubMed ID: 29123081
[TBL] [Abstract][Full Text] [Related]
8. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
Caldwell SA; Ryan MH; McDuffie E; Abrams SI
J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
[TBL] [Abstract][Full Text] [Related]
9. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy.
Oda SK; Anderson KG; Ravikumar P; Bonson P; Garcia NM; Jenkins CM; Zhuang S; Daman AW; Chiu EY; Bates BM; Greenberg PD
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32860705
[TBL] [Abstract][Full Text] [Related]
10. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
[TBL] [Abstract][Full Text] [Related]
12. Gene transfer of Fas ligand induces tumor regression in vivo.
Arai H; Gordon D; Nabel EG; Nabel GJ
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13862-7. PubMed ID: 9391118
[TBL] [Abstract][Full Text] [Related]
13. Pre-existing Fas ligand (FasL) in cancer cells elicits tumor-specific protective immunity, but delayed induction of FasL expression after inoculation facilitates tumor formation.
Chiu HY; Sun GH; Chen SY; Wang HH; Ho MY; Chu CY; Wu WL; Jhou RS; Tsai YL; Huang RT; Sun KH; Tang SJ
Mol Carcinog; 2013 Sep; 52(9):705-14. PubMed ID: 22488710
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells.
Shimizu M; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
Cancer Immunol Immunother; 1998 Nov; 47(3):143-8. PubMed ID: 9829839
[TBL] [Abstract][Full Text] [Related]
16. Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors.
Bajgain P; Torres Chavez AG; Balasubramanian K; Fleckenstein L; Lulla P; Heslop HE; Vera J; Leen AM
Cancer Immunol Res; 2022 Nov; 10(11):1370-1385. PubMed ID: 36122411
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the Fas-apoptosis-signalling pathway by functional polymorphisms at Fas, FasL and Fadd and their implication in T-cell lymphoblastic lymphoma susceptibility.
Villa-Morales M; González-Gugel E; Shahbazi MN; Santos J; Fernández-Piqueras J
Carcinogenesis; 2010 Dec; 31(12):2165-71. PubMed ID: 20889682
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.
Klebanoff CA; Crompton JG; Leonardi AJ; Yamamoto TN; Chandran SS; Eil RL; Sukumar M; Vodnala SK; Hu J; Ji Y; Clever D; Black MA; Gurusamy D; Kruhlak MJ; Jin P; Stroncek DF; Gattinoni L; Feldman SA; Restifo NP
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212954
[TBL] [Abstract][Full Text] [Related]
19. CD3
Ivanova OK; Sharapova TN; Romanova EA; Soshnikova NV; Sashchenko LP; Yashin DV
J Cell Biochem; 2017 Oct; 118(10):3359-3366. PubMed ID: 28294381
[TBL] [Abstract][Full Text] [Related]
20. Fas ligand is required for resolution of granulomatous experimental autoimmune thyroiditis.
Wei Y; Chen K; Sharp GC; Braley-Mullen H
J Immunol; 2004 Dec; 173(12):7615-21. PubMed ID: 15585889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
